Article
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections.
Antimicrobial agents and chemotherapy - 21 Feb 2020
Scangarella-Oman Nicole E, Ingraham Karen A, Tiffany Courtney A, Tomsho Lynn, Van Horn Stephanie F, Mayhew David N, Perry Caroline R, Ashton Theresa C, Dumont Etienne F, Huang Jianzhong, Brown James R, Miller Linda A
Abstract excerpt
A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized patients with suspected/confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSIs). Evaluating microbiology outcomes and responses were secondary endpoints. Pretreatment isolates recovered from infected lesions...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.